2. BBH is up 67.0 percent year-to-date
Biotech funds, such as the Market Vectors Biotech ETF (BBH | A-56) and the iShares Nasdaq Biotechnology ETF (IBB | A-58) have garnered some of the best returns of all U.S. ETFs in 2013. BBH and IBB are both up 67.0 percent year-to-date.
Their returns have been fueled by increasing mergers and acquisitions, promising new drugs coming to market and more accommodative regulators willing to push all of those drugs out with greater efficiency.
“The two areas where I would expect to be more heavily involved in M&A are cancer and rare diseases, because they’re hot areas within drug development these days,” said Steve Silver, a biotech equity analyst at S&P Capital IQ.
